“As the first STAT6-targeted agent in clinical development, we believe KT-621 has the opportunity to dramatically alleviate the burden of disease for those suffering from AD by offering an effective ...

“As the first STAT6-targeted agent in clinical development, we believe KT-621 has the opportunity to dramatically alleviate the burden of disease for those suffering from AD by offering an ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Speaking of Sanofi, Nurix is working with this big pharma to develop a STAT6 protein degrader to target TH2-mediated inflammatory disorders, such as Asthma, Atopic Dermatitis, and Allergies.

“GS-6791/NX-0479 is one drug candidate emerging from Nurix’s growing pipeline of degrader-based medicines designed to treat inflammation and autoimmune diseases, including our STAT6 degrader ...

Marfan syndrome (MFS) is a heritable connective tissue disorder caused by mutations in the Fibrillin‐1 gene, which encodes the extracellular matrix protein fibrillin‐1. Patients with MFS are ...

Diabetes mellitus (DM) is a chronic metabolic disorder marked by sustained hyperglycemia. These disturbances contribute to extensive damage across various tissues and organs, giving rise to severe ...

1 Health Sciences Faculty, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland 2 PBS Doctoral School, Bydgoszcz University of Science and ...

SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...